Gambro divests French hospital

12/21/1999 6:03 AM EST

Stockholm, Sweden - Gambro AB (Stockholm Stock Exchange: GAMBaST,
GAMBbST), a leading international medical technology and healthcare com-
pany, today announced that it has agreed to sell the French hospital
Résidence du Parc in Marseille to a subsidiary of the French group FD5.
The divestiture does not include the dialysis clinics operation which,
with its 315 patients, is one of the largest in Europe. The hospital has
about 430 employees and has a turnover of about SEK 300 M (USD 35 M),
excluding the dialysis operation. The divestiture results in a capital
loss of SEK 90 M (USD 11 M) and is effective December 31, 1999. The
operation will be deconsolidated in Gambro's accounts as of October 1,
1999. The divestiture is subject to approval by health authorities.

The divestiture of the hospital is part of the ongoing restructuring
program in Gambro and will result in a strategic focusing of the European
clinics operation to renal care.

For further information please contact:
Bengt Modéer, Senior Vice President, Corporate Communications,
tel. +46-8-613 65 00, +46-70-513 65 33
Anna Augustson, European Investor Relations Manager, tel. +46-8-613 65 35,
+46-70-513 65 34
Tim Schoenberg, Vice President, US Investor Relations Manager,
+1-949-425-2185

Gambro is a global medical technology and healthcare company with leading
positions in renal care - services and products - and blood component
technology (BCT). Gambro is one of the leading providers of kidney
dialysis services in the world. Gambro treats about 43,200 patients in 581
clinics worldwide. Renal care products comprise dialyzers, dialysis
machines, blood lines and dialysis concentrates. BCT includes products for
the separation and handling of blood components. The group, with revenue
of approximately SEK 18 billion (USD 2.2 billion), has approximately
17,000 employees in some 40 countries.